Dare Bioscience, Inc. (DARE) income statement
DARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.45+0.02 (+4.90%)
Close on Nov 18, 2026Market cap $6.88MP/E –Yield –
Dare Bioscience, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 53.8%
- Operating margin
- -813.4%
- Net margin
- -804.4%
- Return on equity, FY2025
- 845.5%
Financial strength
- Current ratio
- 0.99
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 74.6%
Valuation
- P/E ratio
- –
- Price to sales
- 5.04
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?